OMG Ozempic is coming in truckloads! To your street.

Medicare GLP-1 coverage may swamp docs

By Tina Reed, Axios Nes

June 15, 2026

Next month's launch of a Medicare program providing weight-loss drugs for $50 a month is expected to unleash pent-up demand for Wegovy, Zepbound and other blockbuster treatments — and create new bottlenecks at doctors' offices.

The big picture: It could become one of the biggest drug rollouts ever — and it could test an already burdened system as seniors seek new GLP-1 prescriptions.

Clinicians worry that could also give short shrift to patient counseling on how to take the injectables and pills, adjust dosages and deal with side effects.

Medicare has been prohibited by law from covering weight-loss drugs.

Where it stands: The new program is part of a deal President Trump struck with Eli Lilly and Novo Nordisk to cut prices for their diabetes and anti-obesity drugs in exchange for access to more patients.

Providers are bracing for an onslaught beginning July 1, with roughly 14 million Medicare beneficiaries overweight or obese, according to KFF.

"I have a long list of people who are just holding their breath until July 1, who just could not afford the medication before," Christopher Weber, a board member of the Obesity Medicine Association, told Axios.

First, though, they'll have to go through a verification process, or "prior authorization," to determine whether they qualify for the low-cost drugs.

"We're already in primary care and obesity medicine kind of overwhelmed with prior authorizations ... this is going to overwhelm a lot of clinics," Weber said.

Medicare administrators have told doctors they are streamlining the process and establishing a central clearinghouse for the reviews.

"In our situation we would have to double or triple our pharmacy team, and to my knowledge, that has not happened in preparation for this," said Annie Moore, an internal medicine doctor at the University of Colorado.